📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
1 analysed today
FollowTelegram
1
Today
151,861
All-time analysed
43,535
Positive
6,743
Negative
92,746
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
846 announcements match the current filters (relevance ≥ 5).
Biocon to Integrate Biocon Biologics, Valuing BBL at USD 5.5 Billion
Biocon Limited will fully integrate Biocon Biologics Limited (BBL) as a wholly-owned subsidiary. Biocon will acquire the remaining stake in BBL from Serum, Tata Capital, and Activ Pine through a share swap of 70.28 Biocon shares for every 100 BBL shares, valuing BBL at USD 5.5 billion. Additionally, Biocon will acquire Viatris' stake for USD 815 million, including USD 400 million in cash and USD 415 million in shares. Biocon plans to raise up to ₹4500 crore (USD 500 million) through QIP to fund the cash component.
Key Highlights
Biocon to acquire Biocon Biologics Limited (BBL) valuing BBL at USD 5.5 billion.
Share swap ratio of 70.28 Biocon shares for every 100 Biocon Biologics shares.
Acquisition of Mylan Inc. stake for USD 815 million, including USD 400 million cash.
Plans to raise up to ₹4500 crore (USD 500 million) through Qualified Institutional Placement (QIP).
👀 What to Watch
Investors should note the share swap ratios and the potential dilution from the QIP. Monitor the progress of the integration, expected to be completed by March 31, 2026, and its impact on Biocon's long-term growth.
Biocon to Fully Integrate Biocon Biologics; Approves ₹6,950 Cr Share Swap and ₹4,500 Cr Fundraise
Biocon's board has approved the acquisition of minority stakes in its subsidiary, Biocon Biologics Limited (BBL), from Mylan, Serum Institute, and others to achieve full integration. The deal involves a preferential share issuance of 17.13 crore shares worth ₹6,950 crore as a swap and a separate cash consideration for Mylan. To fund the cash component, Biocon plans to raise up to ₹4,500 crore through QIP or other routes, supported by an interim ₹1,800 crore commercial paper issuance. This consolidation aims to simplify the corporate structure and create a unified capital allocation strategy by March 2026.
Key Highlights
Acquisition of 40.56 crore shares of Biocon Biologics to achieve 100% ownership and structural simplification.
Preferential issuance of 17.13 crore Biocon Ltd shares valued at approximately ₹6,950 crore to existing BBL minority shareholders.
Planned fundraise of up to ₹4,500 crore via QIP or Rights Issue primarily to settle cash payments to Mylan.
Issuance of ₹1,800 crore in Commercial Papers approved for interim cash requirements during the transition.
Authorized share capital increased from ₹700 crore to ₹900 crore to facilitate the equity expansion.
👀 What to Watch
Investors should view this as a strategic consolidation that simplifies the group structure, though they must account for the significant equity dilution from the ₹6,950 crore swap and the upcoming ₹4,500 crore fundraise. Monitor the pricing of the QIP as it will determine the final impact on earnings per share.
Biocon Pharma gets tentative US FDA nod for Carbidopa and Levodopa capsules
Biocon Limited's wholly-owned subsidiary, Biocon Pharma Limited, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for its ANDA for Carbidopa and Levodopa Extended-Release Capsules. The capsules are in strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg. These capsules are used for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. This approval allows Biocon to potentially enter the market upon patent expiry.
Key Highlights
Biocon Pharma received tentative US FDA approval for Carbidopa and Levodopa Extended-Release Capsules
Capsule strengths approved: 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg
The capsules treat Parkinson's disease and related conditions
👀 What to Watch
This tentative approval is a positive sign for Biocon's expansion in the US market. Investors should monitor the final approval and launch plans for these capsules.
Bikaji invests $250,000 in US subsidiary
Bikaji Foods International has made an additional subscription of $250,000 in its wholly-owned subsidiary, Bikaji Foods International USA Corp. This investment involves the purchase of 25,000 common stocks at $10 each. The aim is to strengthen the distribution network in the USA to enhance market presence and improve customer accessibility. Bikaji USA's turnover for the period ended March 31, 2025, was $1,769,792.
Key Highlights
Invested $250,000 in Bikaji Foods International USA Corp
Purchased 25,000 common stocks at $10 each
Bikaji USA turnover was $1,769,792 for the period ended March 31, 2025
Bikaji USA Authorized Capital: $1,500,000
Bikaji USA Paid-up Capital: $1,150,000
👀 What to Watch
This investment signals Bikaji's intent to expand in the US market; investors should monitor the performance of the US subsidiary and its contribution to Bikaji's overall revenue in the coming quarters.
Biocon Biologics Secures Europe Entry for Denosumab Biosimilars Starting Dec 2, 2025
Biocon Biologics has settled with Amgen Inc., clearing the path to commercialize its Denosumab biosimilars, Vevzuo® and Evfraxy®, in Europe and the rest of the world starting December 2, 2025. This follows the European Commission's approval in July 2025 and a previous settlement for the U.S. market. The products target significant markets, including 32 million osteoporosis patients in Europe and oncology-related bone health, strengthening Biocon's global biosimilar portfolio of 10 commercialized assets.
Key Highlights
Settlement with Amgen allows market entry for Denosumab biosimilars in Europe from December 2, 2025.
Commercialization includes Vevzuo® for oncology and Evfraxy® for osteoporosis and bone loss.
Targets a European market of 32 million individuals aged 50+ with osteoporosis and 2.74 million annual cancer cases.
Follows prior U.S. market entry settlements, broadening Biocon's reach in the oncology and bone health therapeutic areas.
Biocon Biologics currently serves over 6 million patients across 120+ countries with 10 commercialized biosimilars.
👀 What to Watch
Investors should monitor the revenue ramp-up from these launches in late 2025, as they represent a significant expansion into the high-value European biosimilars market. The resolution of legal hurdles with Amgen reduces uncertainty regarding Biocon's global commercialization timeline.
SBIN: Shri Anindya Sunder Paul Appointed DMD (Finance) & KMP Eff. 01.12.2025
State Bank of India (SBIN) announced the appointment of Shri Anindya Sunder Paul as Deputy Managing Director (Finance) and Key Managerial Personnel (KMP), effective December 1, 2025. This disclosure is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The previous communication regarding this matter was referenced in letter no. CC/S&B/AND/2025-26/466 dated 17.09.2025. The appointment signifies a change in the bank's key management team.
Key Highlights
Shri Anindya Sunder Paul takes over as DMD (Finance) effective 01.12.2025
Appointment disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015
Referenced letter no. CC/S&B/AND/2025-26/466 dated 17.09.2025
👀 What to Watch
Investors should monitor the performance and strategic decisions of the new DMD (Finance) and its potential impact on SBIN's financial performance. No immediate action is required.
